Postoperative VR for Recovery After Bariatric Surgery
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04754165 |
|
Recruitment Status :
Not yet recruiting
First Posted : February 15, 2021
Last Update Posted : February 8, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Bariatric Surgery Candidate Postoperative Pain Postoperative Complications | Other: Virtual Reality Immersive Relaxation | Not Applicable |
The investigators propose conducting a randomized, controlled, single-center clinical trial of patients recovering from laparoscopic bariatric surgery. The objective is to investigate whether the use of virtual reality (VR) during the immediate postoperative period could improve patient reported quality of recovery and potentially reduce opioid analgesic requirements as compared to an existing ERAS protocol.
The investigators hypothesize that immersive VR will improve subjective quality of recovery scores at time of Post Anesthesia Care Unit (PACU) discharge as compared to standard ERAS.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 105 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Research participants will be randomized to one of two groups: immersive VR plus ERAS, or ERAS alone in a 1:1 allocation. The first 5 patients enrolled will be assigned to the VR group for the purposes of a pilot phase with the objective of identifying and refining any issues with the intervention. Data for these patients will not be included in the statistical analysis. |
| Masking: | Single (Outcomes Assessor) |
| Masking Description: | Assessors of the QOR15 recovery scale will be blinded to group assignment. |
| Primary Purpose: | Treatment |
| Official Title: | Postoperative Virtual Reality (VR) for Recovery After Bariatric Surgery |
| Estimated Study Start Date : | February 1, 2022 |
| Estimated Primary Completion Date : | June 30, 2023 |
| Estimated Study Completion Date : | September 30, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Immersive Virtual Reality plus the enhanced recovery after surgery protocol
Patients in the immersive VR group will don a VR headset connected to a software platform on a tablet, as well as noise cancelling headphones in the post anesthesia care unit (PACU) after surgery. Patients can choose their desired experience within the VR software from a selection of immersive environments and/or video content. Examples include sitting in a canoe on a river, on a peaceful meadow or in a forest. Patients also have the option to listen to guided meditation or select from a library of videos to watch on a web-based user interface. Patients in the VR group will also be treated according to the existing enhanced recovery after surgery protocol. |
Other: Virtual Reality Immersive Relaxation
The VR software developed allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation. |
|
No Intervention: Enhanced recovery after surgery protocol
Subjects in the control group will only undergo standard enhanced recovery after surgery care.
|
- Quality of Recovery Questionnaires (QoR-15) [ Time Frame: Measured at time of post anesthesia care unit discharge, on average of 1 to 5 hours after surgery. ]The primary outcome of this study will be patient reported quality of recovery at time of PACU discharge, as assessed by the QOR-15. The QOR-15 is a validated instrument to assess postoperative recovery from the patient's perspective, assessing overall well-being, nausea, pain, and anxiety and depression following surgery.
- PACU Opioid Requirements [ Time Frame: Measured throughout a patient's stay in the post anesthesia care unit, on average 1 to 5 hours after surgery. ]The postoperative opioid requirements following the patients surgery, will be measured in milligrams and converted to morphine dose equivalents.
- Length of PACU stay [ Time Frame: Duration of the patient's stay in the post anesthesia care unit, from time of admission to time of readiness for PACU discharge, on average 1 to 5 hours. ]The length of the patients stay in the Post Anesthesia Care Unit will be measured in minutes.
- PACU pain scores using numeric rating scale [ Time Frame: Administered every hour following admission to the post anesthesia care unit until discharge from the post anesthesia care unit, on average 1 to 5 hours. ]Clinically documented pain scores will be recorded on a scale from 0 (best outcome) to 10 (worst outcome).
- Postoperative Quality of Recovery Questionnaires (QoR-15) score [ Time Frame: Measured at 24 hours after post anesthesia unit discharge. ]The QOR-15 is a validated instrument to assess postoperative recovery from the patient's perspective, assessing overall well-being, nausea, pain, and anxiety and depression following surgery.
- Hospital length of stay [ Time Frame: Measured throughout the patients stay at the hospital, on average 1 to 3 days. ]The length of the patients stay following surgery.
- Opioid requirements [ Time Frame: Measured throughout the patients stay at the hospital, on average 1 to 3 days. ]Opioid requirements throughout the hospital stay.
- Opioid-related adverse effects [ Time Frame: Measured throughout the patients stay at the hospital, on average 1 to 3 days. ]Opioid-related adverse effects such as nausea or ileus.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients undergoing laparoscopic bariatric surgery at BIDMC under general anesthesia.
Exclusion Criteria:
- Age<18
- Open wounds or active infection of the face or eye area
- History of seizures or other symptom linked to an epileptic condition
- Patients who plan to wear hearing aids during the procedure
- Patients with a pacemaker or other implanted medical device
- Droplet or airborne precautions (as determined by BIDMC infection control policy)
- Non English Speaking
- Chronic opioid dependence (existing oral opioid prescription for >3 months, methadone, suboxone)
Drop Out Criteria: (after enrollment and randomization, before intervention)
- Surgery is converted to an open procedure (laparotomy), the patient will be withdrawn from the study as these patients are treated in a manner that is different than standard ERAS protocols
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04754165
| Contact: Brian P O'Gara, MD,MPH | 617-754-3189 | bpogara@bidmc.harvard.edu | |
| Contact: Evynne Gartner, BA | egartner@bidmc.harvard.edu |
| United States, Massachusetts | |
| Beth Israel Deaconess Medical Center | |
| Boston, Massachusetts, United States, 02215 | |
| Contact: Brian P. O'Gara, MD, MPH 617-754-3189 bpogara@bidmc.harvard.edu | |
| Principal Investigator: Brian O'Gara, MD, MPH | |
| Principal Investigator: | Brian P O'Gara, MD,MP | Beth Israel Deaconess Medical Center |
| Responsible Party: | Brian O'Gara, Assistant Professor of Anaesthesia, Beth Israel Deaconess Medical Center |
| ClinicalTrials.gov Identifier: | NCT04754165 |
| Other Study ID Numbers: |
2020P001149 |
| First Posted: | February 15, 2021 Key Record Dates |
| Last Update Posted: | February 8, 2022 |
| Last Verified: | January 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Virtual Reality ERAS |
|
Postoperative Complications Pathologic Processes |